Posted by Michael Wonder on 15 Jan 2020
TLV has decided to reconsider the subsidy for Xeljanz
14 January 2020 - When TLV decided that Xeljanz should be included in the high-cost protection, this was justified by the fact that the cost of use was lower than the TNF inhibitor comparison option.
Since then, the cost of TNF inhibitors has decreased, which means that the cost of using Xeljanz today is higher than for most TNF inhibitors.
TLV therefore finds reasons to reconsider the decision with the aim of investigating whether there is a need to limit the subsidy for Xeljanz.
